• Human trials begin to­day in California using Celularity's CYNK-001 inves­ti­ga­tional immuno­therapy as part of a national clin­i­cal trial that will en­roll approx­i­mately 86 adults who tested COVID-19 pos­i­tive
• CYNK-001 is the only cryo­pre­served allo­geneic, off-the-shelf NK cell ther­apy devel­oped from pla­cen­tal hema­to­poietic stem cells.

Warren, NJ (Press Release) – Celularity an­nounced to­day that the first patient was dosed in a Phase I/II study of human pla­cen­tal hema­to­poietic stem cell derived NK cells (CYNK-001) for the treat­ment of adults with COVID-19 as part of a national clin­i­cal trial. The patient was treated at UC Irvine in California, the first CA site to open for patient en­roll­ment with sup­port from a COVID-19 Project grant awarded to Celularity by the California In­sti­tute for Regenerative Medicine (CIRM). Par­tic­i­pat­ing trial sites in­clude …

CYNK-001, the com­pany's allo­geneic, off-the-shelf, cryo­pre­served Natural Killer cell ther­apy to be used in Phase I/II study

Warren, NJ (Press Release) – Celularity Inc. ("Celularity" or the "Com­pany"), a clin­i­cal-stage com­pany devel­op­ing allo­geneic cel­lu­lar ther­a­pies from human pla­cen­tas, to­day an­nounced the U.S. Food and Drug Admin­istra­tion (FDA) has cleared the Com­pany's Inves­ti­ga­tional New Drug (IND) appli­ca­tion for the use of its pro­pri­e­tary CYNK-001 in adults with COVID-19. With this, Celularity will com­mence a Phase I/II clin­i­cal study in­clud­ing up to 86 patients with COVID-19. The Com­pany be­lieves CYNK-001 is the first immuno­therapy IND cleared by the FDA to treat COVID-19 infected adults.

"This IND rep­re­sents a sig­nif­i­cant step to­ward a po­ten­tial …